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• Question: Are there patterns of atopic eczema activity into adulthood?  
• Findings: Among over 30,905 participants followed from birth into mid-life four patterns of 
activity were identified: high probability, decreasing, increasing, and low probability of atopic 
eczema across ages. Early life factors did not differentiate the active subtypes, and the subtype 
with increasing probability of activity had the highest risk of poor self-reported health in mid-
life.  
• Meaning: The probability of atopic eczema remains high into adulthood for a subgroup of 
patients, and a newly identified subtype with increasing probability of activity in adulthood 





Importance: Atopic eczema is characterized by a heterogenous waxing and waning course, with 
variable age of onset and persistence of symptoms. Distinct patterns of disease activity such as 
early-onset/resolving and persistent disease have been identified throughout childhood; little is 
known about patterns into adulthood. 
Objectives: To identify subtypes of atopic eczema based on patterns of disease activity through mid-
adulthood, to examine whether early life risk factors and participant characteristics predict these 
subtypes, and to determine whether subtypes are associated with other atopic diseases and general 
health in mid-adulthood.  
Design: Two population-based birth cohort studies.  
Setting: United Kingdom, 1958-2016.  
Participants: Members of the 1958 National Childhood Development Study (NCDS) and the 1970 
British Cohort Study (BCS70). 
Main outcomes and measures: Subtypes of atopic eczema patterns were identified based on self-
reported atopic eczema period prevalence at multiple occasions. These subtypes were the outcome 
in models of early life characteristics and an exposure variable in models of mid-life health.  
Results: Latent class analysis identified four subtypes with distinct patterns of disease activity among 
15,939 individuals from the NCDS and 14,966 individuals from the BCS70: ‘rare/no’ atopic eczema 
(88-91%), ‘decreasing’ (4%), ‘increasing’ (2-6%), and persistently ‘high’ (2-3%) probability of 
reporting prevalent atopic eczema with age. Early life factors, including sex at birth, social class, 
region of residence, tobacco smoke exposure, and breastfeeding, predicted differences between the 
three atopic eczema subtypes and the infrequent/no atopic eczema group, but only female sex 
differentiated the high and decreasing probability subtypes. Individuals in the high subtype were 
most likely to experience asthma and rhinitis, and those in the increasing subtype were at higher risk 
of poor self-reported general (OR 1.29, 95%CI 1.09 to 1.53) and mental (OR 1.45, 95%CI 1.23 to 1.72) 
health in mid-life.  
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Conclusions and Relevance: Extending the window of observation beyond childhood, we observed 
clear subtypes of atopic eczema based on patterns of disease activity. A newly identified subtype 
with increasing probability of activity in adulthood warrants additional attention given observed 




 Atopic eczema (also known as atopic dermatitis or eczema)1 affects up to 20% of children in 
industrialized settings, 2-5 and is characterized by a heterogenous waxing and waning course, with 
variable age of onset and persistence of symptoms. Prior studies have identified differences in 
patterns of disease activity throughout childhood. In particular, subtypes with resolving disease in 
childhood have been identified, and early onset during the first two years of life has been associated 
with genetic variants and development of asthma and allergies.6-10  
 Newer research has shown that atopic eczema is also common among adults, affecting 7-
10% of the UK and US populations.11-13 There is a lack of studies that prospectively examine the 
course of atopic eczema beyond adolescence/early adulthood, and a more comprehensive 
understanding of disease activity across the lifespan is needed.14,15 Data on long-term disease course 
may offer insight into mechanisms for disease onset and persistence, are important when 
counselling patients, and would establish baseline trajectories for future studies of whether new 
treatments can modify disease course and development of comorbidities.  
 Using two British population-based longitudinal birth cohorts with over 40 years of follow-
up, we previously found that the majority of adults with atopic eczema had symptom onset after 
childhood, and that there were important differences in risk factor profiles between those with 
childhood-onset and adult-onset disease.16 However, this study may not fully represent the real-
world heterogeneity in disease course.  
Herein our objectives were to identify subtypes of atopic eczema based on patterns of 
disease activity from birth through mid-adulthood, to examine whether early life risk factors and 
participant characteristics predict these subtypes, and to determine whether the subtypes are 




We used data from the 1958 National Child Development Study (NCDS) and 1970 British 
Cohort Study (BCS70), which are ongoing, multidisciplinary studies that include 17,415 and 17,196 
individuals born in Great Britain during one week in March 1958 and March 1970, respectively.17,18 
There have been 9 subsequent waves of follow up in each cohort at approximately 5-10 year 
intervals. In the NCDS, we excluded the waves at ages 33, 46, and 55 because atopic eczema data 
were not collected, and we excluded individuals without any data on the presence/absence of 
symptoms of atopic eczema (N=1,476 for NCDS; N=2,230 for BCS70). Additional information on 
response patterns in both cohorts has been reported elsewhere.19,20  
Identification of atopic eczema subtypes based on disease activity over time 
We used latent class analysis (LCA) to identify subtypes of atopic eczema activity patterns 
based on parental or self-reported atopic eczema period prevalence from standardized questions \ 
at 6 (NCDS) to 9 (BCS70) waves of follow up (eTable 1). This measure was previously shown to 
coincide with standardized clinical examinations among children in the NCDS,21,22 and a similar 
question demonstrated high sensitivity and specificity for physician-diagnosed atopic eczema in US 
populations.23  
We ran generalized linear latent and mixed models with increasing numbers of latent 
classes. To select the number of classes, we examined model fit statistics, the estimated class sizes, 
and clinical interpretation.24 Models with lower adjusted Bayesian Information Criteria (BIC) values 
and higher entropy values that produced subtypes including >2% of the population were preferred.  
We estimated the posterior latent class (subtype) probabilities and examined their 
distributions. Probabilities close to 1 suggest a trajectory is well-classified and distinct from the other 
subtype trajectories. Individuals were assigned to the class for which they had the highest posterior 
probability. We visually evaluated the consistency of individual patterns of disease activity within 
each class using heatmaps with a dendrogram,    
 
Identification of early- and mid-life factors associated with atopic eczema subtypes 
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We examined associations between early life factors and the newly identified atopic eczema 
subtypes, which were considered categorical outcomes in multinomial logistic regression models. 
Early-life factors were selected a priori based on literature showing associations with childhood 
atopic eczema and adult-onset eczema in the British birth cohorts.16,21,25,26  Adjusted models included 
sex, ethnic group, history of any breastfeeding, region of residence in childhood, childhood smoke 
exposure (either parent reporting current smoking at age 5 in the BCS70, and age 16 in the NCDS), 
household size (<=3 persons vs. 4+ persons), maternal in utero smoke exposure, birth weight, and 
the Registrar General’s designation of social class in childhood (a standard measure based on the 
father’s highest occupational status reported on any survey at ages 0-10/11). Data on parental 
history of asthma and hay fever were only available in the BCS70 at age 5 years.  
Next, we examined whether atopic eczema subtype (now as a predictor variable) was 
associated with binary outcomes of self-reported asthma, hay fever, general health, and mental 
health in separate multivariable logistic regression models adjusted for sex, ethnicity, social class, 
and cohort. Asthma and rhinitis were based on self-report of the condition at age 46 (BCS70) or age 
50 (NCDS, eTable1). General health was assessed using the 36-Item Short Form Health Survey (SF-
36) at age 50 (NCDS) and age 46 (BCS70).27 We used a derived score based on five questions in the 
general health domain that ranged from 1 to 100, with higher scores indicating a more positive self-
assessment of health, as the outcome in a linear regression model.28 To compare with other 
analyses, we also dichotomized responses from a single question from the SF-36 about general 
health (“Excellent/very good/good” vs “fair/poor”). Mental health was assessed using the Malaise 
Inventory scale at age 42. Based on previous literature, a cut-off of >=7 (of 24 items) and >=4 (of 
nine items) was used to define high risk of psychiatric morbidity for NCDS and BCS70, respectively.29 
We performed all regressions separately in each cohort, and after evaluating for 
consistency, we conducted a meta-analysis of individual participant data, assuming fixed effects 
across studies and accounting for the clustering of participants within cohorts.  
Sensitivity analyses  
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Because the timing of questions about atopic eczema period prevalence varied slightly 
across cohorts (eTable 1), we performed a sensitivity analysis repeating the cohort specific LCAs 
using only five time points that were most consistent across both cohorts.     
Missing data 
The LCA method accommodates missing outcome (atopic eczema) data with full information 
maximum likelihood estimation, therefore we used all available atopic eczema data in both cohorts 
and assessed individual patterns of missingness using heat maps. We performed multiple imputation 
in each cohort separately with iterative chained equations to impute missing early-life data (see 
supplemental methods for details). The imputed results were compared to the complete case 
analysis. We did not impute data on atopic comorbidities or general/mental health in mid-life 
because most of the missing data were due to attrition.  
This study was exempt from IRB approval because no identifiable information was accessed 
by the study team. Statistical analyses were conducted using Stata, version 16 (StataCorp, College 
Station TX).  
 
Results 
The study sample included 15,939 individuals from the NCDS and 14,966 from the BCS70. 
Atopic eczema was reported at >1 time point(s) by 16.7% and 24.4% of participants in the NCDS and 
BCS70, respectively. Demographic and early-life characteristics for both cohorts are presented in 
Table 1.  
Atopic eczema subtypes based on disease activity over time 
Model fit statistics demonstrated that 5-class models performed slightly better than 4-class 
models, however, the additional class included only 1% of the sample in each cohort, resulted in 
lower entropy scores, and did not improve the clinical interpretation (eFigure 1 and eTable 2). 
Therefore, we present results for the four-class model. In this model, participants had a high 
probability of being assigned to their most likely subtype and a low probability of being in the other 
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subtypes (eTable 3), and individual disease trajectories followed a similar overall pattern despite 
individual heterogeneity (eFigure 2).  
We labeled the subtypes in each cohort by the probability of atopic eczema with age: 
‘rare/no atopic eczema’, ‘decreasing’, ‘high’, and ‘increasing’ (Figure 1). The decreasing and high 
subtypes were similar in size in both cohorts, but the increasing subtype was larger in the BCS70 as 
compared to the NCDS (6% vs 2%).  
A sensitivity analysis using only atopic eczema data from the five time points most similar 
between cohorts did not achieve as good of a model fit or separation between the classes in mid-
adulthood as analyses utilizing all available data (eTable 2).   
Early life factors as predictors of atopic eczema subtypes  
We examined associations between atopic eczema subtypes and early life factors using 
rare/no atopic eczema as a reference group. We found that sex, region of residence, social class, in 
utero smoke exposure, and breastfeeding were associated with differences in disease trajectory 
subtype (Table 2). Female sex was associated with higher odds of the high and increasing subtypes 
and a lower odds of the decreasing subtype as compared to rare/no atopic eczema group. Those 
who resided in Northern England or Scotland during childhood experienced lower odds of all 
subtypes of atopic eczema than those who resided in Southern England. Those from higher 
childhood social class and who were breastfed were more likely to be in the high and decreasing 
subtypes. Parental history of atopic disease in the BCS70 was a significant predictor of all atopic 
eczema subtypes as compared to the rare/no atopic eczema group (eTable 4).  
Using the same regression models but changing the comparison group to examine 
differences between atopic eczema subgroups, we found that only female sex was associated with 
an increased risk of the high subtype as compared to the decreasing subtype (Table 3). Residence in 
Central England as compared to Southern England was also associated with an increased risk of the 
high subtype, but the full geography variable did not meet statistical significance as an independent 
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predictor (p=0.100). Female sex and lower childhood social class were associated with increasing as 
compared to decreasing subtypes.  
Associations between disease trajectory subtypes with other atopic disease, general health, and 
mental health in mid-life 
Those classified into the highly probable atopic eczema subtype consistently had the highest 
prevalence of asthma/wheeze and rhinitis, and those classified into the no/rare atopic eczema 
subtype had the lowest rates (eTable 5). Compared to the no/rare atopic eczema subtype, all other 
subtypes had an increased odds of asthma and rhinitis in mid-life (Table 4). The increasing and high 
subtypes were both associated with worse self-reported general health, and only the increasing 
subtype was associated with poor mental health (Table 4).  
Sensitivity and missing data analyses  
Primary results described above use the combined and imputed cohort. Additional analyses 




 Leveraging two large population-based birth cohorts with repeated assessments of 
individual atopic eczema disease activity, we identified four distinct disease trajectories based on 
probability of reporting atopic eczema with age: a majority of people who report no atopic eczema 
or who report it rarely, decreasing probability, high probability, and increasing probability of 
reporting atopic eczema with age. Previously identified early life risk factors including sex, region of 
residence, parental social class, in utero smoke exposure and breastfeeding were associated with 
the atopic eczema subtypes as compared to those with rare or no atopic eczema, but only female 
sex helped to differentiate the high from decreasing subtype. A newly identified subtype with 
increasing probability of atopic eczema with age was most likely to have poor self-reported general 
and mental health in mid-life.  
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Comparison to existing literature 
There is a lack of clarity regarding the terminology around atopic eczema/atopic 
dermatitis/eczema. We chose to use the term ‘atopic eczema’ because ‘atopic dermatitis’ is less 
commonly used in the UK, and using the term ‘eczema’ alone is not recommended.30 The term 
‘atopic’ does not necessarily indicate the presence of atopy; in many population-based cohorts, 
most patients do not demonstrate IgE-specific antibodies to common environmental allergens.31   
 We previously found differences between cohort participants who reported childhood-
onset versus adulthood-onset atopic eczema.16 Our current analysis represents a substantial 
additional contribution because we used a hypothesis-free approach to identify distinct subtypes 
based on data from all ages and were able to compare predictors and outcomes between those 
subtypes. These subtypes describe age-associated probabilities, not individual disease trajectories. 
Thus, we chose probabilistic labels such as ‘increasing’ rather than ‘late-onset,’ since an individual in 
the increasing probability subtype may not necessarily have late-onset disease: 21% of individuals in 
NCDS and 27% in BCS70 classified into this subtype experienced atopic eczema symptoms at some 
point in childhood (prevalence of atopic eczema by subtype and age shown in eTable 5).  
 While other studies have examined atopic eczema subtypes based on disease activity 
across childhood;6-10  ours is unique in its duration of follow-up into mid-life which allowed for 
identification of a new subtype with an increasing probability of atopic eczema over time. This 
subtype was associated with poor general and mental health in mid-life. An Australian study that 
examined asthma trajectories over many decades similarly found that late-onset asthma was most 
strongly associated with general health.32 Other studies show that the immune profile of atopic 
eczema varies by age, but haven’t yet examined disease course.33,34 These results indicate that 
disease duration and activity may be important in predicting outcomes and should be included in 
studies of atopic eczema comorbidities.   
 Geographic and temporal differences suggest that environmental factors may influence 
disease course. Geographic location was associated with all the atopic eczema subtypes in our study. 
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A prior study using NCDS data found that regional differences in both examined and reported 
eczema were maintained when data were analyzed at the county level.22 There were also temporal 
differences: atopic eczema was more common in the BCS70, which is consistent with secular trends 
documented in other data sources,35,36 and the increasing subtype was larger in the BCS70 (6% vs 2% 
in the NCDS). This may indicate it is becoming more common, though additional studies are needed 
to confirm this finding. Environmental factors including temperature and humidity, water hardness, 
pollution levels, and the environmental microbiome have been linked to AD and may vary 
geographically and temporally.22,37-39 Future research should examine the role of environmental 
factors on patterns and persistence of atopic eczema over time.  
 Breastfeeding was associated with a higher risk of all the atopic eczema subtypes in our 
study, and in utero smoke exposure was associated with a lower risk of the high subtype. In the 
literature, there have been mixed findings on these factors.40,41 Women with a history of atopy may 
be less likely to smoke and more likely to breastfeed, which could explain our results. Additionally, 
the timing and duration of smoking and breastfeeding are likely to be important, as well as potential 
confounding by social factors we were unable to control for in our study. Given the constraints of 
historical data analysis, we were unable to further examine these issues. The health risks of smoking 
and benefits of breastfeeding are both well-established,42,43 and our results should not be 
interpreted as implying otherwise.  
   
Limitations  
While our study relied on two large, generalizable cohorts with five decades of follow-up, it 
was also limited by missing data and lack of clinical detail. We performed multiple imputation to 
address missing early life data and did not identify patterns indicative of bias due to attrition. The 
reliance on self-report of atopic eczema could result in misclassification bias. Self-report has been 
shown to reasonably approximate clinical assessment in childhood21,22 and physician diagnosis in 
adulthood,23 and is unlikely to be differential over time among individuals. Both cohorts had similar 
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population-based designs, but the wording and timing of questions differed between cohorts 
(eTable1). A prior investigation did not find evidence of bias due to changes in study design.44 A 
methodological limitation is that allocating individuals to their most likely latent class then analyzing 
these classes as if they were observed may overstate precision in the analytical models. However, 
given the high level of entropy and average posterior class membership probabilities, this is unlikely 
to be a major limitation. 
We could not examine atopic eczema severity or how treatment patterns affect disease 
course, which is an important area for future research. For example, among adults with mild asthma, 
early initiation of inhaled corticosteroid treatment may improve long-term outcomes. As more 
systemic treatments become available for atopic eczema,45 randomized trials to examine whether 
these treatments affect disease trajectory are of utmost importance. Our results help establish a 
baseline for long-term disease course.  
 
Conclusion 
 When extending the window of observation beyond childhood, clear subtypes of atopic 
eczema based on patterns of disease activity emerged. In particular, a newly identified subtype with 
increasing probability of activity in adulthood warrants additional attention given associations with 
poor self-reported physical and mental health in mid-life. Early life factors shown to be associated 
with childhood atopic eczema overall did not help differentiate between subtypes raising the 
possibility that disease trajectory is modifiable and may be influenced by environmental factors 
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Figure 1. Estimated probabilities of atopic eczema symptoms at each age for each subtype in 4-class 









Table 1. Patient characteristics by cohort 






















Asthma       
No 12633 (79.3%) 10809 (81.4%) 1824 (68.5%) 11996 (80.2%) 9359 (82.7%) 2637 (72.1%) 
Any 3238 (20.3%) 2402 (18.1%) 836 (31.4%) 2300 (15.4%) 1355 (12.0%) 945 (25.8%) 
Missing 68 (0.4%) 67 (0.5%) 1 (0.0%) 670 (4.5%) 596 (5.3%) 74 (2.0%) 
Rhinitis       
No 11718 (73.5%) 10140 (76.4%) 1578 (59.3%) 9624 (64.3%) 7836 (69.3%) 1788 (48.9%) 
Any 4149 (26.0%) 3066 (23.1%) 1083 (40.7%) 5329 (35.6%) 3467 (30.7%) 1862 (50.9%) 
Missing 72 (0.5%) 72 (0.5%) 0 (0.0%) 13 (0.1%) 7 (0.1%) 6 (0.2%) 
Sex       
   Male 8200 (51.4%) 6996 (52.7%) 1204 (45.2%) 7716 (51.6%) 6110 (54.0%) 1606 (43.9%) 
   Female 7739 (48.6%) 6282 (47.3%) 1457 (54.8%) 7250 (48.4%) 5200 (46.0%) 2050 (56.1%) 
Ethnicity       
White  12018 (75.4%) 9843 (74.1%) 2175 (81.7%) 11790 (78.8%) 8758 (77.4%) 3032 (82.9%) 
Other 160 (1.0%) 132 (1.0%) 28 (1.1%) 510 (3.4%) 389 (3.4%) 121 (3.3%) 
    Missing 3761 (23.6%) 3303 (24.9%) 458 (17.2%) 2666 (17.8%) 2163 (19.1%) 503 (13.8%) 
Region of residence 
in childhood 
      
Southern England 4871 (30.6%) 4014 (30.2%) 857 (32.2%) 4427 (29.6%) 3177 (28.1%) 1250 (34.2%) 
Central England 4689 (29.4%) 3866 (29.1%) 823 (30.9%) 3454 (23.1%) 2555 (22.6%) 899 (24.6%) 
Northern England 6379 (40.0%) 5398 (40.7%) 981 (36.9%) 4804 (32.1%) 3718 (32.9%) 1086 (29.7%) 
Missing 0 (0.0) 0 (0.0%) 0 (0.0%) 2281 (15.3%) 1860 (16.4%) 421 (11.5%) 
Social class in 
childhoodd 
      
I/II 4489 (28.2%) 3632 (27.4%) 857 (32.2%) 5281 (35.3%) 3780 (33.4%) 1501 (41.1%) 
IIIa/b 9626 (60.4%) 8069 (60.8%) 1557 (58.5%) 8410 (56.2%) 6504 (57.5%) 1906 (52.1%) 
IV/V 1718 (10.8%) 1479 (11.1%) 239 (9.0%) 1238 (8.3%) 995 (8.8%) 243 (6.6%) 
Missing 106 (0.7%) 98 (0.7%) 8 (0.3%) 37 (0.2%) 31 (0.3%) 6 (0.2%) 
Household size       
<=3 persons 1211 (7.6) 996 (7.5%) 215 (8.1%) 1339 (8.9) 999 (8.8%) 340 (9.3%) 
4+ persons 12357 (77.5) 10186 (76.7%) 2171 (81.6%) 11374 (76.0) 8471 (74.9%) 2903 (79.4%) 
Missing 2371 (14.9) 2096 (15.8%) 275 (10.3%) 2253 (15.1) 1840 (16.3%) 413 (11.3%) 
Smoking during 
pregnancy 
      
No 10482 (65.8%) 8690 (65.4%) 1792 (67.3%) 8050 (53.8%) 5963 (52.7%) 2087 (57.1%) 
Any 5257 (33.0%) 4427 (33.3%) 830 (31.2%) 6847 (45.8%) 5293 (46.8%) 1554 (42.5%) 
Missing 200 (1.3%) 161 (1.2%) 39 (1.5%) 69 (0.5%) 54 (0.5%) 15 (0.4%) 
Childhood smoke 
exposure 
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No 2993 (18.8%) 2424 (18.3%) 569 (21.4%) 4340 (29.0%) 3165 (28.0%) 1175 (32.1%) 
Any 7953 (49.9%) 6564 (49.4%) 1389 (52.2%) 8337 (55.7%) 6272 (55.5%) 2065 (56.5%) 
Missing 4993 (31.3%) 4290 (32.3%) 703 (26.4%) 2289 (15.3%) 1873 (16.6%) 416 (11.4%) 
Parental history of 
atopy  
      
No --- --- --- 8638 (57.7%) 6687 (59.1%) 1951 (53.4%) 
Any --- --- --- 2958 (19.8%) 1918 (17.0%) 1040 (28.4%) 
Missing --- --- --- 3370 (22.5%) 2705 (23.9%) 665 (18.2%) 
Birth weight (kg), 
mean (SD) 
3.3 (0.5) 3.3 (0.5) 3.3 (0.5) 3.3 (0.5) 3.3 (0.5) 3.3 (0.5) 
Missing 529 (3.3%) 445 (3.4%) 84 (3.2%) 14 (0.1%) 13 (0.1%) 1 (0.03%) 
Breastfeeding       
No 4435 (27.8%) 3742 (28.2%) 693 (26.0%) 7957 (53.2%) 6075 (53.7%) 1882 (51.5%) 
Any 9583 (60.1%) 7832 (59.0%) 1751 (65.8%) 4659 (31.1%) 3323 (29.4%) 1336 (36.5%) 
Missing 1921 (12.1%) 1704 (12.8%) 217 (8.2%) 2350 (15.7%) 1912 (16.9%) 438 (12.0%) 
Notes:  
aNational Childhood Development Survey 
b1970 British Cohort Study 
cN is based on patients with at least one response to an eczema question, missing refers to number of 
individuals without data on each covariate.  










Table 2. Association between early life factors and subtypes as compared to rare/no AE subtype 
(results of 1958 and 1970 meta-analysis) (Total N across all classes = 30,905) 
 
 
aRegion of early childhood residence: overall p-values are 0.01 for high vs rare/no AE, <0.001 for decreasing vs 
rare/no AE, and 0.04 for increasing vs rare/no AE 
bRegistrar General’s social class: I Professional, II Managerial and technical; III Skilled; IV Partly-skilled; V 
Unskilled. 
cHighest social class in childhood: overall p-values are <0.001 for high vs rare/no AE, <0.001 for decreasing vs 










 OR (95% CI) 
Demographic / Early life factors 
Sex    
Male Reference Reference Reference 
Female 1.76 (1.53, 2.04) 0.89 (0.79, 0.99) 1.77 (1.56, 2.01) 
Ethnicity    
European, Caucasian Reference Reference Reference 
Other 0.89 (0.53, 1.48) 1.03 (0.72, 1.46) 0.86 (0.59, 1.25) 
Region of early childhood 
residencea 
   
Southern England Reference Reference Reference 
Central England/Wales 1.06 (0.89, 1.27) 0.85 (0.74, 0.97) 0.93 (0.80, 1.09) 
N. England/Scotland 0.82 (0.69, 0.98) 0.69 (0.60, 0.79) 0.82 (0.70, 0.96) 
Highest social class in 
childhoodb,c 
   
I/II Reference Reference Reference 
III 0.69 (0.59, 0.80) 0.80 (0.71, 0.91) 0.92 (0.80, 1.05) 
IV/V 0.50 (0.37, 0.68) 0.56 (0.44, 0.71) 0.88 (0.69, 1.12) 
Household size in early 
childhood 
   
<=3 persons Reference Reference Reference 
4+ persons 1.02 (0.79, 1.32) 0.95 (0.79, 1.15) 0.93 (0.75, 1.16) 
In utero smoke exposure    
No Reference Reference Reference 
Any 0.83 (0.70, 0.98) 1.00 (0.87, 1.13) 0.91 (0.79, 1.05) 
Childhood smoke exposure    
No Reference Reference Reference 
Any 0.94 (0.78, 1.12) 0.95 (0.82, 1.10) 0.91 (0.79, 1.06) 
Birth weight    
Per kg increase 1.09 (0.95, 1.25) 1.01 (0.91, 1.13) 0.93 (0.83, 1.05) 
Breastfeeding    
No Reference Reference Reference 
Any 1.39 (1.18, 1.63) 1.20 (1.06, 1.36) 1.18 (1.03, 1.35) 
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Table 3. Association between early life factors and atopic eczema activity subtypes as compared to 
the early onset/decreasing subtype for the 1958 and 1970 cohorts meta-analysis (Total N across all 






 OR (95% CI) 
Sex   
Male Reference Reference 
Female 1.99 (1.66, 2.38) 1.99 (1.69, 2.35) 
Ethnicity   
European, Caucasian Reference Reference 
Other 0.86 (0.47, 1.58) 0.84 (0.51, 1.38) 
Region of early childhood residencea   
Southern England Reference Reference 
Central England/Wales 1.26 (1.01, 1.56) 1.10 (0.90, 1.36) 
N. England/Scotland 1.18 (0.95, 1.47) 1.19 (0.97, 1.45) 
Highest social class in childhoodb,c    
I/II Reference Reference 
III 0.86 (0.71, 1.03) 1.14 (0.95, 1.36) 
IV/V 0.90 (0.61, 1.32) 1.58 (1.13, 2.21) 
Household size in early childhood   
<=3 persons Reference Reference 
4+ persons 1.08 (0.79, 1.47) 0.98 (0.75, 1.30) 
In utero smoke exposure   
No Reference Reference 
Any 0.83 (0.68, 1.03) 0.91 (0.76, 1.10) 
Childhood smoke exposure   
No Reference Reference 
Any 0.99 (0.79, 1.23) 0.96 (0.79, 1.18) 
Birth weight   
Per kg increase 1.08 (0.90, 1.28) 0.92 (0.79, 1.08) 
Breastfeeding   
No Reference Reference 
Any 1.16 (0.95, 1.41) 0.98 (0.82, 1.17) 




 OR (95% CI) 
Sex   
Male Reference Reference 
Female 1.99 (1.66, 2.38) 1.99 (1.69, 2.35) 
Ethnicity   
European, Caucasian Reference Reference 
Other 0.86 (0.47, 1.58) 0.84 (0.51, 1.38) 
Region of early childhood residencea   
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Southern England Reference Reference 
Central England/Wales 1.26 (1.01, 1.56) 1.10 (0.90, 1.36) 
N. England/Scotland 1.18 (0.95, 1.47) 1.19 (0.97, 1.45) 
Highest social class in childhoodb,c    
I/II Reference Reference 
III 0.86 (0.71, 1.03) 1.14 (0.95, 1.36) 
IV/V 0.90 (0.61, 1.32) 1.58 (1.13, 2.21) 
Household size in early childhood   
<=3 persons Reference Reference 
4+ persons 1.08 (0.79, 1.47) 0.98 (0.75, 1.30) 
In utero smoke exposure   
No Reference Reference 
Any 0.83 (0.68, 1.03) 0.91 (0.76, 1.10) 
Childhood smoke exposure   
No Reference Reference 
Any 0.99 (0.79, 1.23) 0.96 (0.79, 1.18) 
Birth weight   
Per kg increase 1.08 (0.90, 1.28) 0.92 (0.79, 1.08) 
Breastfeeding   
No Reference Reference 
Any 1.16 (0.95, 1.41) 0.98 (0.82, 1.17) 
aRegion of early childhood residence: overall p-values are 0.10 for high vs decreasing AE and 0.24 for 
increasing vs decreasing AE 
bRegistrar General’s social class: I Professional, II Managerial and technical; III Skilled; IV Partly-skilled; V 
Unskilled. 








aEach column represents a separate logistic or linear regression model predicting the odds of each health outcome. The rows shows different reference groups for the 







Poor mental health 
at age 42 
N=17,978 
Poor general health 
at age 46/50 
N=18,733 
SF-36 General Health at age 46/50 
N=15,810 
 OR (95% CI) Mean difference (95% CI) 
Rare/no AE Reference Reference Reference Reference Reference 
High AE 3.45 (2.82, 4.21) 2.70 (2.24, 3.26) 1.06 (0.85, 1.32) 1.26 (1.03, 1.55) -1.24 (-3.21, 0.73) 
Decreasing AE 1.70 (1.38, 2.10) 1.42 (1.18, 1.70) 0.89 (0.73, 1.08) 0.88 (0.72, 1.07) 0.03 (-1.67, 1.73) 
Increasing AE 2.11 (1.75, 2.53) 1.92 (1.64, 2.25) 1.45 (1.23, 1.72) 1.29 (1.09, 1.53) -4.52 (-6.12, -2.92) 
 
Decreasing AE Reference Reference Reference Reference Reference 
High AE 2.02 (1.53, 2.68) 1.91 (1.48, 2.46) 1.20 (0.90, 1.61) 1.44 (1.09, 1.90) -1.27 (-3.82, 1.28) 
Increasing AE 1.24 (0.95, 1.62) 1.36 (1.07, 1.72) 1.64 (1.27, 2.11) 1.47 (1.15, 1.89) -4.55 (-6.83, -2.27) 
 
Increasing AE Reference Reference Reference Reference Reference 
Decreasing AE 0.81 (0.62, 1.06) 0.74 (0.58, 0.93) 0.61 (0.47, 0.79) 0.68 (0.53, 0.87) 4.55 (2.27, 6.83) 
High AE 1.63 (1.26, 2.12) 1.41 (1.11, 1.79) 0.73 (0.56, 0.96) 0.98 (0.75, 1.27) 3.28 (0.79, 5.77) 
